409 related articles for article (PubMed ID: 31814783)
1. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis.
Ganguli S; DeLeeuw P; Satapathy SK
Hepat Med; 2019; 11():159-178. PubMed ID: 31814783
[TBL] [Abstract][Full Text] [Related]
2. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.
Satiya J; Snyder HS; Singh SP; Satapathy SK
Transl Gastroenterol Hepatol; 2021; 6():60. PubMed ID: 34805582
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
4. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
Le TA; Loomba R
J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
[TBL] [Abstract][Full Text] [Related]
5. Murine models provide insight to the development of non-alcoholic fatty liver disease.
Reid DT; Eksteen B
Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
[TBL] [Abstract][Full Text] [Related]
6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
7. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
8. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
9. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments.
Sasaki A; Nitta H; Otsuka K; Umemura A; Baba S; Obuchi T; Wakabayashi G
Front Endocrinol (Lausanne); 2014; 5():164. PubMed ID: 25386164
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
13. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects.
Laursen TL; Hagemann CA; Wei C; Kazankov K; Thomsen KL; Knop FK; Grønbæk H
World J Hepatol; 2019 Feb; 11(2):138-149. PubMed ID: 30820265
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics in non-alcoholic fatty liver disease.
Lee J; Kim Y; Friso S; Choi SW
Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.
Higuera-de la Tijera F; Servín-Caamaño AI
World J Hepatol; 2015 Jun; 7(10):1297-301. PubMed ID: 26052375
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of non-alcoholic fatty liver disease.
Sugimoto K; Takei Y
Hepatol Res; 2011 Oct; 41(10):911-20. PubMed ID: 21951869
[TBL] [Abstract][Full Text] [Related]
17. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Fatty Liver Disease: The Present and the Future.
Ramanan SP; Mohamed MWF; Aung SS; Sange I; Hamid P
Cureus; 2021 Jan; 13(1):e12713. PubMed ID: 33614318
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
